Entity

Time filter

Source Type

Berlin, Germany

Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2011-ITN | Award Amount: 4.30M | Year: 2012

STROMA is an Initial Training Network promoting the study of stromal cell immune system interactions during stroma development and function in health and disease. In STROMA we have bought together world leading experts from academia and industry in Europe to address the key scientific questions in this emerging field. STROMA will promote the training of three Experienced Researchers (ER) and seventeen Early Stage Researchers (ESR) combining research and training in state-of-the-art multidisciplinary technologies. Through hands on and a Virtual Learning Environment STROMA will train the ESRs in the latest imaging, animal models, genomics, infectious biology and stromal biology technologies in collaboration with our industrial partners. STROMA will provide training in communications skills, ethics, plagiarism, grant writing, intellectual property rights, industrial skills training, project management, entrepreneurship, research policy, commercial exploitation of results and public engagement and develop a Personal Training Plan for each ESR and ER. Through network meetings and localized training the ESRs will receive additional training in complementary skills. STROMA is a highly interconnected network with each ER/ESR project involving multiple collaborations and secondments with other network participants including an extensive placement with our industrial partners. The importance of stromal cells and the molecular mechanism of stromal cell function in the regulation of immune responses have only recently been appreciated and are an exciting new area in immunology. The purpose of STROMA is to ensure that Europe retains global leadership in this emerging field and translates basic research on stroma-immune cell interactions to novel products and technologies for European industry.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.0-1 | Award Amount: 6.97M | Year: 2013

Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to do better than Nature, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.


Trademark
Probiogen Ag | Date: 2009-06-30

Biological preparations for diagnostic, pharmaceutical, medical and veterinary purposes, namely, preparations developed from biological cells; biological preparations for medical and veterinary purposes, namely, cell cultures, cell lines in the nature of designer cell lines, and cell substrates for pharmaceutical, medical and veterinary purposes, for manufacturing vaccines, proteins, and other pharmaceutical active substances; vaccines, antibodies and proteins for diagnostic, pharmaceutical, medical and veterinary purposes, namely, active pharmaceutical ingredients for the therapeutical, preventive and in vitro diagnostic use. Scientific and industrial biological research and development, namely, manufacture of proteins and vaccines with the aid of biological cells, including cell line design; Medical laboratory services, namely, manufacture of proteins and vaccines with the aid of biological cells and cell line design. Licensing of intellectual property.


Trademark
Probiogen Ag | Date: 2009-06-30

Biological preparations for diagnostic, pharmaceutical, medical and veterinary purposes, namely, preparations developed from biological cells; biological preparations for medical and veterinary purposes, namely, cell cultures, cell lines in the nature of designer cell lines, and cell substrates for pharmaceutical, medical and veterinary purposes, for manufacturing vaccines, proteins, and other pharmaceutical active substances; Vaccines, antibodies and proteins for diagnostic, pharmaceutical, medical and veterinary purposes, namely, active pharmaceutical ingredients for the therapeutical, preventive and in vitro diagnostic use. Scientific and industrial biological research and development, namely, manufacture of proteins and vaccines with the aid of biological cells, including cell line design; Medical laboratory services, namely, manufacture of proteins and vaccines with the aid of biological cells and cell line design. Licensing of intellectual property.


Trademark
Probiogen Ag | Date: 2009-08-18

Biological preparations for diagnostic, pharmaceutical, medical and veterinary purposes, namely, preparations developed from biological cells; biological preparations for medical and veterinary purposes, namely, cell cultures, cell lines in the nature of designer cell lines, and cell substrates for pharmaceutical, medical and veterinary purposes, namely, for manufacturing vaccines, proteins, and other pharmaceutical active substances; vaccines, antibodies and proteins for diagnostic, pharmaceutical, medical and veterinary purposes, namely, active pharmaceutical ingredients for the therapeutical, preventive and in vitro diagnostic use. Scientific and industrial biological research and development, namely, manufacture of proteins and vaccines with the aid of biological cells, including cell line design; Medical laboratory services, namely, manufacture of proteins and vaccines with the aid of biological cells and cell line design. Licensing of intellectual property.

Discover hidden collaborations